Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

2nd International Conference on Drug Discovery 2026

from around the world to explore groundbreaking innovations in drug research, pharmaceutical sciences, and biotechnology. The 2nd International Conference on Drug Discovery 2026, organized by Scisynopsis Conferences, aims to bring together...

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines Inc., a biotechnology company developing first-in-class therapies targeting cancer stem cells, announced that its second ADAR1p150 protein crystallization experiment has successfully launched aboard the SpaceX CRS-34 commercial...

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or...

Viralgen Teams with Elaaj Bio to Advance CDKL5 Deficiency Gene Therapy

in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deficiency Disorder (CDD). Elaaj Bio is a wholly owned...

UCB to acquire Candid Therapeutics, strengthening its immunology pipeline with novel T-cell engagers

of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). This...

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present advancements related to TfR1 CapX™. A leading...

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

1 mg to target doses of 40 mg, 60 mg and 80 mg. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics...

Orca Bio Announces FDA Extension of BLA Review for Orca-T in the Treatment of Hematologic Malignancies.

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of its Biologics License...

CellCentric Launches DOMMINO-1, a Phase 2 Trial of Inobrodib Combined with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating...

ProductLife Group Appoints Dr. James Burt as CEO

in 150+ countries, operations in 50+ countries, and a team of over 2,000 professionals, PLG supports pharmaceutical, biotechnology, medical device, nutrition and cosmetics companies in accelerating innovation, ensuring compliance and improving...

Emerging From Stealth, Oryon Cell Therapies Targets Autologous Neuron Replacement for Parkinson’s Disease and Neurodegenerative Disorders

Oryon Cell Therapies a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21...

Convergent Therapeutics Appoints Michael Rossi to Board

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, announced the appointment of Michael Rossi to its Board of Directors. Mr. Rossi...

Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

track record of building and leading clinical operations in both established biopharma organizations and emerging biotechnology companies,” said Behzad Kharabi, M.D., chief medical officer of 3T Biosciences. “Her pragmatic, quality-focused approach...

Neurizon Begins Dosing of NUZ-001 in HEALEY ALS Platform Trial

Neurizon® Therapeutics Limited a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS...

Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

Matricelf Ltd. a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and...

Unique Mouse Model Enables genOway to Transform Prediction of Antibody Therapies in Humans

and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University...

ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

U.S., announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners. The Innovation Central Laboratory will serve as an ecosystem for validating technologies...

With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

with outstanding fidelity,” said Professor Yehia Mechref, Director of the Texas Tech University Center for Biotechnology & Genomics. “The new software capabilities—especially eXd N-glycopeptide analysis and improved top-down workflows—support...

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals Holding Corp. a fully integrated, commercial biotechnology company, presented data on TONMYA™, which was investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit, on January 29, 2026, in Boston,...

Results 1 - 20 of 132